A Phase 3b, Multicenter, Open-label, Single-arm, Expanded Access Protocol of Talimogene Laherparepvec for the Treatment of Subjects in Europe With Unresected Stage IIIB to IVM1c Melanoma

Trial Profile

A Phase 3b, Multicenter, Open-label, Single-arm, Expanded Access Protocol of Talimogene Laherparepvec for the Treatment of Subjects in Europe With Unresected Stage IIIB to IVM1c Melanoma

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Jun 2017

At a glance

  • Drugs Talimogene laherparepvec (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions; Expanded access; Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 12 Jun 2017 Status changed from recruiting to active, no longer recruiting.
    • 26 Nov 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top